Ugonma Nnenna Chukwueke, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Central Nervous System Neoplasms | 7 | 2023 | 915 | 2.250 |
Why?
|
| Brain Neoplasms | 19 | 2024 | 9025 | 1.230 |
Why?
|
| Meningeal Neoplasms | 6 | 2024 | 1246 | 0.890 |
Why?
|
| Oligodendroglioma | 2 | 2022 | 278 | 0.880 |
Why?
|
| Meningeal Carcinomatosis | 5 | 2024 | 63 | 0.760 |
Why?
|
| Glioblastoma | 7 | 2024 | 3482 | 0.710 |
Why?
|
| Astrocytoma | 1 | 2022 | 774 | 0.590 |
Why?
|
| Meningioma | 3 | 2022 | 1216 | 0.580 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 303 | 0.540 |
Why?
|
| Medical Oncology | 5 | 2024 | 2320 | 0.510 |
Why?
|
| Benchmarking | 1 | 2021 | 1045 | 0.490 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2022 | 1372 | 0.460 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 858 | 0.440 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 1405 | 0.320 |
Why?
|
| Clinical Trials as Topic | 4 | 2024 | 8003 | 0.310 |
Why?
|
| Glioma | 1 | 2022 | 3452 | 0.290 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2813 | 0.250 |
Why?
|
| Combined Modality Therapy | 3 | 2022 | 8519 | 0.220 |
Why?
|
| Societies | 1 | 2021 | 107 | 0.180 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2023 | 237 | 0.180 |
Why?
|
| DNA Modification Methylases | 1 | 2020 | 210 | 0.170 |
Why?
|
| Oncolytic Viruses | 1 | 2023 | 344 | 0.170 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 13632 | 0.170 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2023 | 301 | 0.160 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2019 | 65 | 0.160 |
Why?
|
| World Health Organization | 2 | 2022 | 1321 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2020 | 350 | 0.160 |
Why?
|
| DNA Repair Enzymes | 1 | 2020 | 346 | 0.160 |
Why?
|
| Patient Selection | 2 | 2022 | 4246 | 0.160 |
Why?
|
| Medically Underserved Area | 1 | 2021 | 254 | 0.160 |
Why?
|
| Central Nervous System | 2 | 2023 | 1333 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 348 | 0.150 |
Why?
|
| Herpesvirus 1, Human | 1 | 2023 | 739 | 0.150 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 515 | 0.150 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2020 | 610 | 0.150 |
Why?
|
| Pyridazines | 1 | 2019 | 202 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2020 | 638 | 0.150 |
Why?
|
| Melanoma | 1 | 2016 | 5694 | 0.140 |
Why?
|
| Humans | 38 | 2024 | 761208 | 0.140 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 3873 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 5809 | 0.140 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2022 | 937 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 11733 | 0.130 |
Why?
|
| Cytodiagnosis | 1 | 2019 | 447 | 0.130 |
Why?
|
| Methotrexate | 1 | 2022 | 1718 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 424 | 0.120 |
Why?
|
| Pulmonary Emphysema | 2 | 2010 | 683 | 0.110 |
Why?
|
| Imidazoles | 1 | 2019 | 1172 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2022 | 1600 | 0.110 |
Why?
|
| Ovarian Neoplasms | 2 | 2020 | 4872 | 0.100 |
Why?
|
| Disease Management | 2 | 2024 | 2507 | 0.100 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 4909 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2019 | 1499 | 0.100 |
Why?
|
| Mutation | 6 | 2024 | 30002 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2019 | 1084 | 0.100 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 955 | 0.100 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 13385 | 0.090 |
Why?
|
| Socioeconomic Factors | 2 | 2022 | 7804 | 0.090 |
Why?
|
| Attitude to Health | 1 | 2019 | 2026 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 2803 | 0.090 |
Why?
|
| Genomics | 3 | 2024 | 5828 | 0.090 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 2576 | 0.090 |
Why?
|
| Immunotherapy | 3 | 2021 | 4642 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 2047 | 0.080 |
Why?
|
| Pulmonary Alveoli | 2 | 2010 | 651 | 0.080 |
Why?
|
| Adult | 12 | 2024 | 221119 | 0.080 |
Why?
|
| Nausea | 2 | 2021 | 678 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2527 | 0.070 |
Why?
|
| Ceramides | 1 | 2008 | 200 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 9278 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2020 | 4384 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3608 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 3253 | 0.070 |
Why?
|
| Emphysema | 1 | 2008 | 238 | 0.060 |
Why?
|
| Neoplasms | 3 | 2024 | 22140 | 0.060 |
Why?
|
| Decision Making | 1 | 2019 | 3931 | 0.060 |
Why?
|
| Superoxide Dismutase | 1 | 2008 | 593 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2023 | 10088 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 5333 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 5662 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 20982 | 0.050 |
Why?
|
| Apoptosis | 2 | 2008 | 9477 | 0.050 |
Why?
|
| United States | 4 | 2024 | 72339 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2023 | 64681 | 0.050 |
Why?
|
| Transcription Factors | 3 | 2024 | 12099 | 0.050 |
Why?
|
| Anorexia | 1 | 2021 | 152 | 0.050 |
Why?
|
| Middle Aged | 8 | 2021 | 220853 | 0.050 |
Why?
|
| Incidence | 1 | 2019 | 21365 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2023 | 3634 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2023 | 424 | 0.040 |
Why?
|
| Aged | 6 | 2022 | 169288 | 0.040 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2020 | 102 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 2871 | 0.040 |
Why?
|
| Female | 11 | 2022 | 392544 | 0.040 |
Why?
|
| Hepatitis | 1 | 2021 | 228 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2019 | 166 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 329 | 0.040 |
Why?
|
| Receptor, TIE-2 | 1 | 2019 | 176 | 0.040 |
Why?
|
| Random Allocation | 1 | 2023 | 2393 | 0.040 |
Why?
|
| Genes, myc | 1 | 2020 | 390 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2022 | 793 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2024 | 850 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 559 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 4574 | 0.030 |
Why?
|
| Vomiting | 1 | 2020 | 650 | 0.030 |
Why?
|
| Exanthema | 1 | 2021 | 503 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2019 | 546 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2019 | 371 | 0.030 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 3354 | 0.030 |
Why?
|
| Smoking | 2 | 2010 | 9055 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2019 | 558 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 2023 | 10203 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2008 | 3551 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2329 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 706 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 1386 | 0.030 |
Why?
|
| Awareness | 1 | 2019 | 649 | 0.030 |
Why?
|
| Minority Groups | 1 | 2022 | 1201 | 0.030 |
Why?
|
| Consensus | 1 | 2024 | 3134 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2019 | 1867 | 0.030 |
Why?
|
| Forecasting | 1 | 2023 | 2928 | 0.030 |
Why?
|
| Lung | 2 | 2010 | 9979 | 0.030 |
Why?
|
| Fatigue | 1 | 2021 | 1550 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 2549 | 0.030 |
Why?
|
| Child | 1 | 2022 | 80152 | 0.030 |
Why?
|
| Fever | 1 | 2021 | 1618 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1089 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2020 | 3605 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2023 | 1468 | 0.030 |
Why?
|
| Travel | 1 | 2019 | 796 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2010 | 3577 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2021 | 3155 | 0.030 |
Why?
|
| Colitis | 1 | 2021 | 1234 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2019 | 943 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2024 | 3446 | 0.030 |
Why?
|
| Male | 8 | 2022 | 360693 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2024 | 3923 | 0.030 |
Why?
|
| Educational Status | 1 | 2019 | 2510 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2020 | 1375 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 2024 | 0.020 |
Why?
|
| Seizures | 1 | 2024 | 2965 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2020 | 4243 | 0.020 |
Why?
|
| Piperazines | 1 | 2021 | 2522 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2451 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 6819 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 6486 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2024 | 5782 | 0.020 |
Why?
|
| Pyridines | 1 | 2021 | 2872 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2019 | 2726 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2019 | 3493 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 10756 | 0.020 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2008 | 82 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 3788 | 0.020 |
Why?
|
| Oxidative Stress | 2 | 2008 | 3114 | 0.020 |
Why?
|
| Superoxides | 1 | 2008 | 388 | 0.020 |
Why?
|
| Research Design | 1 | 2022 | 6180 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2019 | 8642 | 0.020 |
Why?
|
| Cell Line | 1 | 2020 | 15545 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 11067 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 3092 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 8530 | 0.020 |
Why?
|
| Mice | 4 | 2020 | 81326 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 20119 | 0.020 |
Why?
|
| Disease Progression | 1 | 2022 | 13511 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2008 | 23416 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 58952 | 0.010 |
Why?
|
| Macrophages | 1 | 2019 | 5753 | 0.010 |
Why?
|
| Cytokines | 1 | 2019 | 7386 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 5300 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14675 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 1168 | 0.010 |
Why?
|
| Organ Size | 1 | 2008 | 2253 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2022 | 80674 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2020 | 22174 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2010 | 2475 | 0.010 |
Why?
|
| Ligands | 1 | 2008 | 3264 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 2058 | 0.010 |
Why?
|
| Animals | 4 | 2020 | 168079 | 0.010 |
Why?
|
| Prognosis | 1 | 2020 | 29687 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 6199 | 0.010 |
Why?
|
| Homeostasis | 1 | 2010 | 3320 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2008 | 3661 | 0.010 |
Why?
|
| Cell Survival | 1 | 2008 | 5778 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 41496 | 0.010 |
Why?
|
| Peptides | 1 | 2008 | 4353 | 0.010 |
Why?
|
| Protein Binding | 1 | 2008 | 9297 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 9520 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2010 | 14392 | 0.010 |
Why?
|
| Brain | 1 | 2020 | 27092 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 9457 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 22127 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 18220 | 0.000 |
Why?
|